Abstract
Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P
| Original language | English |
|---|---|
| Pages (from-to) | 211-217 |
| Number of pages | 7 |
| Journal | Journal of Diabetes and its Complications |
| Volume | 17 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2003 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes : Influence of prior antidiabetic drug regimen. / Rendell, Marc S.; Glazer, N. Bradly; Ye, Zhan.
In: Journal of Diabetes and its Complications, Vol. 17, No. 4, 07.2003, p. 211-217.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes
T2 - Influence of prior antidiabetic drug regimen
AU - Rendell, Marc S.
AU - Glazer, N. Bradly
AU - Ye, Zhan
PY - 2003/7
Y1 - 2003/7
N2 - Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P
AB - Purpose: To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. Subjects and Methods: The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Results: Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA1C) levels during the 16-week course of the trial (-1.0±0.1 [mean±S.E.] percentage points; P1C levels (0.2±0.2 percentage points; P>.05). The difference between groups was significant (P1C levels (-1.0±0.1 and -1.4±0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P1C levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P
UR - http://www.scopus.com/inward/record.url?scp=0142029431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142029431&partnerID=8YFLogxK
U2 - 10.1016/S1056-8727(03)00005-9
DO - 10.1016/S1056-8727(03)00005-9
M3 - Article
C2 - 12810245
AN - SCOPUS:0142029431
VL - 17
SP - 211
EP - 217
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
SN - 1056-8727
IS - 4
ER -